PDCD1 and non-small cell lung carcinoma: So, IT is considered one of the most important breakthroughs in cancer treatment of the past decade; notably, different studies of PD-1 and PD-L1 inhibitors have reported impressive clinical activity and durable responses in patients with advanced NSCLC.